Nina Capital Launches Clinical Advisory Board with Internationally Recognized Physicians

Four internationally recognized physician leaders in interventional neurology, medical imaging, and drug development join the firm's inaugural Clinical Advisor.

BARCELONA, SPAIN, September 7, 2026 /EINPresswire.com/ -- Nina Capital is thrilled to announce the formation of its Clinical Advisory Board. Dr. Tudor G. Jovin, Prof. Gabriel P. Krestin, Prof. Lluís Donoso-Bach, and Dr. Pietro Scalfaro have joined the Board to provide clinical and scientific guidance to the firm and its portfolio companies.

They join Nina Capital's inaugural Clinical Advisor, Dr. Paul Yock (United States), a National Medal of Technology and Innovation laureate (2024) and the founder of Stanford Biodesign, which he established in 2001 to turn health-technology innovation into a teachable discipline.

The Board will advise Nina Capital on clinical evidence, product strategy, and regulatory and reimbursement pathways. It will also give portfolio founders direct access to clinical networks and expertise across interventional neurology, medical imaging, and drug development.

Dr. Tudor G. Jovin (United States) is Chairman and Chief of Neurology and Medical Director of the Cooper Neurological Institute at Cooper University Health Care in Camden, New Jersey, and Professor of Neurology and Neurosurgery at Cooper Medical School of Rowan University. An internationally recognized interventional and vascular neurologist, he led the landmark REVASCAT, DAWN, BAOCHE, and LASTE trials that transformed the treatment of acute ischemic stroke.

Prof. Gabriel P. Krestin (Netherlands) is Professor Emeritus of Radiology at Erasmus MC in Rotterdam and a past President of the European Society of Radiology. He previously chaired Erasmus MC's Department of Radiology and Nuclear Medicine for nearly 25 years, building it into one of Europe's leading imaging departments, and founded the European Institute for Biomedical Imaging Research. He is a member of the U.S. National Academy of Medicine and Academia Europaea.

Prof. Lluís Donoso-Bach (Spain) is President of the Fundació Món Clínic Barcelona and an Honorary Professor of Radiology at the University of Barcelona. He is the former Director of Diagnostic Imaging at Hospital Clínic de Barcelona. A former President of both the European Society of Radiology and the Spanish Society of Medical Radiology, Prof. Donoso-Bach has been a

leading figure in the digital transformation of medical imaging. Under his leadership, the R&D team developed innovative imaging technologies, patents, and products that have been adopted in clinical practice across Spain.

Dr. Pietro Scalfaro (Switzerland) is a physician and Chief Medical Officer at ENYO Pharma, a clinical-stage biopharmaceutical company, with extensive experience in clinical development across infectious diseases. Trained in pediatrics and intensive care at Lausanne University Hospital, he spent more than a decade at Debiopharm, where he led development programs including alisporivir for hepatitis C, and has held board roles at diagnostics companies including Biocartis and Agendia. He is also the clinical co-founder of Rivia.

"Nina Capital was founded on the conviction that specialized industry insight is the strongest filter in healthtech investing," said Marta G. Zanchi, Founder and Managing Partner of Nina Capital. "Our new Clinical Advisory Board brings that insight directly into our work. These four physicians have shaped stroke care, medical imaging, and drug development at the highest level. Their guidance will sharpen our diligence, strengthen our portfolio companies, and ultimately improve patient outcomes."

About Nina Capital

Nina Capital is a venture capital firm investing in technology-enabled healthcare companies across Europe, the United States, the United Kingdom, Canada, Israel, and Australia. The firm partners with founders building the next generation of technology-enabled healthcare products and services.

Marta G. Zanchi
NINA CAPITAL
email us here
Visit us on social media:
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/939670107

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.